All In Biotech

Drug Trial Radar · NCT01255761

A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects

Phase 4, Randomized, 52-Week Study To Evaluate Two Assessment Tools To Predict Treatment Success At 52 Weeks Based On A Treatment Decision At Week 12 In Subjects With Moderate To Severe Rheumatoid Arthritis Receiving Cimzia

Last checked: Nov 20, 2026Latest source record: Jul 31, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 736 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

736

Actual

Start

Nov 2010

Primary completion

Oct 2012

Study completion Dec 2012

Sponsor

Lead sponsor
UCB PharmaUCB
Sponsor type
Industry
First posted
Dec 7, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 4 study to evaluate a routine patient completed assessment (RAPID3) compared to a physician completed assessment (CDAI) to predict treatment success with subjects with moderate to severe rheumatoid arthritis

Conditions

  • Rheumatoid Arthritis

Interventions

  • Certolizumab Pegol (CZP)Biological

    400 mg subcutaneous injection at Weeks 0, 2 and 4 200 mg subcutaneous injection every two weeks, Week 6 through Week 52

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response at Week 12 as Assessed by Randomized Tool [Clinical Disease Activity Index (CDAI) or Routine Assessment of Patient Index Data 3 (RAPID3)]Time frame: Baseline (Week 0) to Week 12
  2. Responders at Week 12 (as Assessed by Randomized Tool Clinical Disease Activity Index [CDAI] or Routine Assessment of Patient Index Data [RAPID3]) Achieving Low Disease Activity (Disease Activity Score 28 [Erythrocyte Sedimentation Rate]≤3.2) at Week 52Time frame: Baseline (Week 0) to Week 52

Locations

110 sites in 1 country. Site status is shown where the registry gives one.

  • 137

    Birmingham, Alabama

  • 166

    Huntsville, Alabama

  • 165

    Peoria, Arizona

  • 216

    Tucson, Arizona

  • 168

    Hot Springs, Arkansas

  • 241

    Jonesboro, Arkansas

  • 153

    Little Rock, Arkansas

  • 111

    Covina, California

  • 208

    Escondido, California

  • 103

    Fullerton, California

  • 155

    Huntington Beach, California

  • 202

    La Mesa, California

  • 203

    Loma Linda, California

  • 233

    Los Angeles, California

  • 105

    Palm Desert, California

  • 229

    Roseville, California

  • 113

    Sacramento, California

  • 127

    San Diego, California

  • 106

    Santa Maria, California

  • 172

    Santa Monica, California

  • 212

    Upland, California

  • 231

    Van Nuys, California

  • 158

    Whittier, California

  • 121

    Bridgeport, Connecticut

  • 200

    Bridgeport, Connecticut

  • 107

    Danbury, Connecticut

  • 195

    Danbury, Connecticut

  • 138

    Hamden, Connecticut

  • 218

    Lewes, Delaware

  • 108

    Aventura, Florida

  • 120

    Dunedin, Florida

  • 101

    Ocala, Florida

  • 225

    Orange Park, Florida

  • 227

    Ormond Beach, Florida

  • 184

    Palm Harbor, Florida

  • 145

    Sarasota, Florida

  • 191

    Tampa, Florida

  • 236

    Vero Beach, Florida

  • 144

    Atlanta, Georgia

  • 232

    Atlanta, Georgia

Showing 40 of 110 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.